Artivion Inc.
AORT | NYSE
$23.43
+$0.08 (+0.34%)
Sep 21, 2026, 3:06 PM ET · Market open
Company Profile
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Key Executives
| Name | Position |
|---|---|
| James Patrick Mackin | Chairman, President & Chief Executive Officer |
| Lance A. Berry | EVice President, Chief Operating Officer, Chief Financial Officer & Treasurer |
| Amy D. Horton | Vice President & Chief Accounting Officer |
| Andrew Green | Senior Vice President of Regulatory & Quality |
| Jason D. Asper | Senior Vice President and Chief Strategy & Digital Officer |
| Jean F. Holloway | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary |
| John E. Davis | Senior Vice President & Chief Commercial Officer |
| Matthew A. Getz | Vice President of Human Resources & Chief Human Resources Officer |
| Robert C. Thomson | Vice President of Research & Development |
| Simona Zannetti | Senior Vice President of Clinical Research & Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 15, 2026 | 4 | Filing |
Artivion Inc.
| Country | United States |
| IPO Date | Feb 11, 1993 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 1,800 |
| CEO | James Patrick Mackin |
Contact Details
1655 Roberts Boulevard N.W. Kennesaw,
Georgia 30144 United States
Stock Details
| Ticker Symbol | AORT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000784199 |
| CUSIP Number | 228903100 |
| ISIN Number | US2289031005 |
| SIC Code | 3841 |
Recent News
- 2 months ago / marketbeat.comArtivion Q2 Earnings Call Highlights
- 2 months ago / seekingalpha.comArtivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comArtivion (AORT) Q2 Earnings Meet Estimates
- 2 months ago / prnewswire.comArtivion Reports Second Quarter 2026 Financial Results
- 2 months ago / prnewswire.comArtivion to Participate in Upcoming Investor Conferences
- 2 months ago / prnewswire.comArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
- 3 months ago / zacks.comArtivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
- 3 months ago / seekingalpha.comArtivion: PMA Approval Supports Accelerating Growth And Margin Expansion
- 3 months ago / prnewswire.comArtivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
- 3 months ago / prnewswire.comArtivion to Participate in the 2026 Truist Securities MedTech Conference
Add to Watchlist
Select watchlists to add or remove AORT